News | October 04, 2022
Fluor bags award for Biologics manufacturing facility in Scandinavia
Construction is now underway with the facility scheduled to be operational by 2025
Construction is now underway with the facility scheduled to be operational by 2025
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
With the receipt of the EIR, the inspection stands successfully closed.
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
Site Enhances New Modality CRDMO Platform Capacity for Customers
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Subscribe To Our Newsletter & Stay Updated
